Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver (Q40202250)

18 September 2017

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver (English)

1 reference

18 September 2017

1 reference

Au T

1

1 reference

18 September 2017

Thorne S

2

1 reference

18 September 2017

Korn WM

3

1 reference

18 September 2017

Sze D

4

1 reference

18 September 2017

Kirn D

5

1 reference

18 September 2017

Reid TR

6

1 reference

18 September 2017

1 December 2006

1 reference

18 September 2017

1 reference

18 September 2017

14

1 reference

18 September 2017

139-150

1 reference

18 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700988

18 September 2017

0 references

cites work

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

First-line therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Replicating viruses as selective cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

ONYX-015 selectivity and the p14ARF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Infection of Mouse Liver by Human Adenovirus Type 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Functions and mechanisms of action of the adenovirus E3 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Adenovirus genes that modulate the sensitivity of virus-infected cells to lysis by TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Ethanol, oxidative stress, and cytokine-induced liver cell injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700988

The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis

21 January 2018

1 reference

12 December 2020

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

1 reference

12 December 2020

Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus

1 reference

12 December 2020

Adenovirus region E3 proteins that prevent cytolysis by cytotoxic T cells and tumor necrosis factor.

1 reference

12 December 2020

Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance

1 reference

12 December 2020

Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection

1 reference

12 December 2020

Special considerations in interpreting liver function tests

1 reference

12 December 2020

p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication

1 reference

12 December 2020

Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study

1 reference

12 December 2020

Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat

1 reference

12 December 2020

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints

1 reference

12 December 2020

Cancer-specific viruses and the development of ONYX-015

1 reference

12 December 2020

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer

1 reference

12 December 2020

Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody

1 reference

12 December 2020

The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.CGT.7700988

1 reference

Dimensions Publication ID

18 September 2017

0 references

0 references

1 reference